Elanco CEO Jeffrey Simmons Buys Company Stock

Jeffrey Simmons, the President, CEO, and Director of Elanco Animal Health Incorporated, recently purchased 115 shares of the company's stock. The transaction, which took place on June 26, 2026, was valued at approximately $2,825.55, with an average purchase price of $24.57 per share. This insider buying activity was not part of a pre-planned trading program, indicating a personal decision by Simmons.

Insider Buying and Selling at Elanco Animal Health Incorporated

In addition to Jeffrey Simmons's purchase, other Elanco insiders have also been active in acquiring shares. On the same day, Robert Vanhimbergen, EVP and CFO, and Rajeev Modi, who is noted as 'See Remarks', bought 8 and 60 shares respectively, at the same price of $24.57 per share. Earlier, on June 12, 2026, Simmons also bought 117 shares at $24.17 each.

Other Institutional Activity in Elanco Animal Health

Several institutional investors have adjusted their holdings in Elanco Animal Health. Dodge & Cox reduced its position by 10,140,205 shares, ending with 68,944,100 shares valued at approximately $1.65 billion, a 12.8% decrease. FMR LLC trimmed its stake by 1,270,955 shares to hold 50,925,366 shares worth about $1.22 billion, a 2.4% decrease. BlackRock, Inc. increased its holdings by 1,287,233 shares, bringing its total to 47,622,630 shares valued at roughly $1.14 billion, a 2.8% increase. Primecap Management Co/CA/ slightly reduced its position by 373,132 shares, holding 45,840,956 shares valued at $1.10 billion.

Elanco Animal Health Incorporated Stock Up 2.9%

Shares of NYSE:ELAN traded near $24.74 on Wednesday. Elanco Animal Health boasts a market cap of about $12.27 billion and trades at a forward P/E ratio of 20.67. The stock has a 52-week range between $13.39 and $27.72, with a 50-day moving average of $23.02 and a 200-day moving average of $22.76. The company's beta is 1.696, indicating higher volatility compared to the market. Elanco maintains a current ratio of 2.156 and a quick ratio of 0.952, with a debt-to-equity ratio of 66.154.

Recent Earnings

Elanco Animal Health reported revenue of $4.89 billion, showing a growth of 14.9%. However, the company is currently not profitable, with a net margin of -4.95% and a return on equity of -3.77%. The next earnings report is scheduled for August 6, 2026.

Analysts Set New Price Targets

Analysts have been bullish on Elanco Animal Health, with TD Cowen maintaining a 'buy' rating and a target price of $32.00 as of June 18, 2026. Citigroup and JP Morgan have also maintained 'buy' ratings with price targets of $31.00 and $30.00, respectively, in May 2026. The consensus among 14 analysts is a strong buy, with a target mean price of $29.86.

About Elanco Animal Health Incorporated

Elanco Animal Health Incorporated, based in Indianapolis, Indiana, is a leading player in the healthcare sector, focusing on animal health. The company develops and markets products for both pets and farm animals, including treatments for parasiticides, vaccines, and therapeutics. Under the leadership of CEO Jeffrey Simmons, Elanco employs around 9,400 people and continues to innovate in the field of animal health.

Bottom Line

Jeffrey Simmons's recent purchase of Elanco stock may signal his confidence in the company's prospects. While insider buying can be a positive indicator, investors should consider the broader financial context. Elanco's stock has shown volatility, and the forward-looking metrics suggest potential for growth, as supported by analyst ratings. As always, remember that past filings and transactions do not necessarily reflect current positions.